**Aims and objectives of this presentation**
Hormone therapy remains the mainstay systemic treatment of advanced prostate cancer. Despite almost 60 years of use, the optimal timing and modalities remain to be determined. This session will focus on recent updates.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (•) are 3 minutes in length, followed by 3 minutes for discussion.

---

### Phase III study of intermittent monotherapy versus continuous combined androgen deprivation
**By:** Calais Da Silva Junior F.¹, Calais Da Silva Senior F.E.², Gonçalves F.³, Kliment J.⁴, Santos A.⁵, Spyros P.⁶, Queimadelos A.⁷, Robertson C.⁸
**Institutes:** CHLC - Hospital De São José, Dept. of Urology, Lisbon, Portugal, ²CHLC - H.S.José, Dept. of Urology, Lisbon, Portugal, ³CUIMED A Saint Michal Hospital, Dept. of Urology, Bratislava, Slovakia, ⁴Jessenius School of Medicine, Dept. of Urology, Martin, Slovakia, ⁵Hospital De Braga, Dept. of Urology, Braga, Portugal, ⁶Amalia Fleming Hospital, Dept. of Urology, Athens, Greece, ⁷Policlinica La Rosaleda, Dept. of Urology, Santiago Compostela, Spain, ⁸University of Strachclyde, Dept. of Statistics, Glasgow, United Kingdom

---

### Survival outcomes in octogenarian and nonagenarian patients treated with first-line androgen deprivation therapy for localized prostate cancer
**By:** Dell'Oglio P.¹, Bishr M.¹, Boehm K.², Trudeau V.¹, Larcher A.³, Tian Z.⁴, Saad F.⁵, Capitanio U.³, Briganti A.³, Graefen M.², Montorsì F.³, Karakiewicz P.¹
**Institutes:** Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, ²Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³Irccs Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ⁴McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, ⁵University of Montreal Health Center, Dept. of Urology, Montreal, Canada

---

### Timing of the development of metastasis and initiation of treatment are important prognostic factors in prostate cancer
**By:** Frees S., Akamatsu S., Lynch K., Chavez-Munoz C., Black P., Gleave M., Goldenberg L., Chi K., So A.
**Institutes:** Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada

---

### Peri-prostatic fat volume predicts castration resistance in advanced prostate cancer
**By:** Hendry J.¹, Patel A.², Leung H.¹, Salji M.¹
**Institutes:** Beatson Institute For Cancer Research, Dept. of Urology, Glasgow, United Kingdom, ²Queen Elizabeth University Hospital, Dept. of Radiology, Glasgow, United Kingdom

---

### Impact of free testosterone levels on the outcome of androgen deprivation therapy in metastatic prostate cancer
**By:** Mandhani A., Agnihotri S., Singh R.
**Institutes:** Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dept. of Urology, Lucknow, India
Degarelix is well tolerated and effective for the treatment of prostate cancer: Results from a phase III study in China
By: Xie L.¹, Bosnyák Z.², Sun Y.³, Malmberg A.², Neijber A.², Fen W.X.⁴
Institutes: ¹The First Affiliated Hospital of College of Medicine, Zhejiang University School of Medicine, Dept. of Urology, Zhejiang Province, China, ²Ferring Pharmaceuticals A/S, Dept. of Global Clinical Research and Development, Copenhagen, Denmark, ³Changchun Hospital The First Affiliated Hospital of The Second Military Medical University (SMMU), Dept. of Urology, Shanghai, China, ⁴Peking University People's Hospital, Dept. of Urology, Beijing, China

Nomograms to estimate castration resistance and cancer specific survival in patients with advanced prostate cancer - GESCAP Study
By: Gómez-Veiga F.¹, Rodriguez-Antolín A.², Miñana B.³, Cozar J.M.⁴, Pedrosa E.⁵
Institutes: ¹Hospital Universitario De Salamanca IBSAL, Dept. of Urology, Salamanca, Spain, ²Hospital Universitario 12 De Octubre, Dept. of Urology, Madrid, Spain, ³Hospital Morales Meseguer, Dept. of Urology, Murcia, Spain, ⁴Hospital Universitario Virgen De Las Nieves, Dept. of Urology, Granada, Spain, ⁵Astellas Pharma S.A., Medical Department, Madrid, Spain

Toremifene plus androgen deprivation therapy (TOPADT) significantly improved biochemical recurrence in bone metastatic prostate cancer: A randomized controlled phase IIA trial
By: Fujimura T.¹, Takahashi S.², Kume H.³, Urano T.³, Takayama K.⁴, Yamada Y.¹, Suzuki M.¹, Fukuhara H.¹, Nakagawa T.¹, Inoue S.¹, Homma Y.¹
Institutes: ¹The University of Tokyo, Dept. of Urology, Tokyo, Japan, ²The Nihon University, Dept. of Urology, Tokyo, Japan, ³The University of Tokyo, Dept. of Geriatric Medicine, Tokyo, Japan, ⁴The University of Tokyo, Dept. of Anti-Aging Medicine, Tokyo, Japan

Clinocopathological features of patients progressed into castration-resistant prostate cancer after radical prostatectomy
By: Yoo S., Han J.H., Shin J., Lee C., You D., Jeong I.G., Hong J., Ahn H., Kim C.S.
Institutes: Asan Medical Center, Dept. of Urology, Seoul, South Korea

The impact of androgen deprivation therapy on body composition and hepatic fat content among men with prostate cancer
By: Ostergren P.B.¹, Chabanova E.², Fode M.³, Bennedbaek F.N.³, Faber J.³, Sonksen J.¹, Kistorp C.³
Institutes: ¹Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen Universi, Dept. of Urology, Herlev, Denmark, ²Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen Universi, Dept. of Radiology, Herlev, Denmark, ³Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen Universi, Dept. of Endocrinology, Herlev, Denmark

Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients
By: Inoue S., Kitano H., Hieda K., Shinmei S., Shoji K., Hayashi T., Teishima J., Matsubara A.
Institutes: Hiroshima University, Dept. of Urology, Hiroshima, Japan

Fracture risk assessment of men treated with androgen deprivation therapy for prostate cancer
By: Turo R.¹, Caliniciuc A.¹, Horsu S.¹, Stephens L.¹, Nikomanis P.¹, Smolski M.², Guler D.¹, Das S.¹, Aiwase N.¹, Pettersson B.¹, Sinclair A.³, Oakley N.³, Adeyoye A.³, Bromage S.³, Brown S.³, Brough R.³, Collins G.³, Cross W.³
Institutes: ¹Countess of Chester Hospital, Dept. of Urology, Chester, United Kingdom, ²Royal Preston Hospital, Dept. of Urology, Preston, United Kingdom, ³Stepping Hill Hospital, Dept. of Urology, Stockport, United Kingdom, ⁴St James's University Hospital, Dept. of Urology, Leeds, United Kingdom

Summary and context
F. Calais Da Silva Junior, Lisbon (PT)